Skip to content

Netherlands logo

Main menu
    • About us
    • Our focus
    • Our products
    • Business development
    • Our leaders
    • Our culture
    • Policies & positions
    • Environmental, social & governance
    • Diversity, equity, inclusion & belonging
    • News
    • Media
  • Join our team

Contact Us

Back
Change Language
  • Nederlands
Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Four in ten women are considering a contraceptive method other than ‘the pill’

Save Print

June 30, 2022 10:09 am EDT

AMSTERDAM – The contraceptive pill is the best known and also the most used contraceptive in the Netherlands and Belgium(1,2). However, many women are thinking about switching to another method, especially women currently using birth control pill.(3) This is evident from a study that healthcare company Organon has commissioned among 2,000 women by research agency IPSOS.

When it comes to contraceptive methods (and other types of protection) the methods to choose from are increasing, but most women between the ages of 18 and 44 in Belgium and the Netherlands mainly use oral contraception, followed by the condom.(2) The IPSOS study shows that 4 out of 10 women consider using another contraception method in the future, especially women who are currently using the contraceptive pill.3) These women prefer long-acting reversible contraception, according to the majority of women in question.(4)

A method that was the best solution at the initial stage no longer has to be the way a few years later. In an issue of Topic Talks gynecologist and director of Ellesie, Els van Doorn, emphasizes that continuing on autopilot is not always the best way to go. “Investigate together with your healthcare provider whether your contraceptive method is still the right one. Many women don’t think about it enough, but with the right birth control you can improve your quality of life and feel happier. (5)

“In the choice (of contraception), the woman is leading,” emphasizes gynecologist Annette ter Haar, also in Topic Talks. “Some women are opposed to oral contraception but open to other forms of birth control.” (6)

It is important that women receive sufficient and correct information to be able to make their choice properly. They can always contact a healthcare professional: women in the Netherlands and Belgium usually select a contraceptive method after consultation with their general practitioner (especially in the Netherlands) or gynecologist (in Belgium). (7)  In addition, information from independent websites can be useful in decision making, such as:

  • NL:
    https://www.zanzu.nl/en/themes/contraception
    www.anticonceptie.nl
    https://seksualiteit.nl/anticonceptietool
  • BE:
    https://www.zanzu.be/en/contraception
    https://www.allesoverseks.be/anticonceptie



VVPM job number IWD survey 2022 IPSOS: NL-NON-110025

What can we help you find?

Search for:
Netherlands logo
  • Forward-Looking Statement
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept